These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 14676228)
1. Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important? Meier JJ; Gallwitz B; Schmidt WE; Mügge A; Nauck MA Heart; 2004 Jan; 90(1):9-12. PubMed ID: 14676228 [TBL] [Abstract][Full Text] [Related]
2. The UGDP controversy: thirty-four years of contentious ambiguity laid to rest. Schwartz TB; Meinert CL Perspect Biol Med; 2004; 47(4):564-74. PubMed ID: 15467178 [TBL] [Abstract][Full Text] [Related]
3. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. Garratt KN; Brady PA; Hassinger NL; Grill DE; Terzic A; Holmes DR J Am Coll Cardiol; 1999 Jan; 33(1):119-24. PubMed ID: 9935017 [TBL] [Abstract][Full Text] [Related]
4. Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing? Leibowitz G; Cerasi E Diabetologia; 1996 May; 39(5):503-14. PubMed ID: 8739909 [TBL] [Abstract][Full Text] [Related]
5. Response to letter by Wang et al.: Comparing cardioprotection by remote ischaemic preconditioning in patients with and without diabetics. Kottenberg E; Peters J Acta Anaesthesiol Scand; 2014 Jul; 58(6):769. PubMed ID: 24850086 [No Abstract] [Full Text] [Related]
6. Comparing cardioprotection by remote ischaemic pre-conditioning in patients with and without diabetes. Wang SY; Xue FS; Cui XL Acta Anaesthesiol Scand; 2014 Jul; 58(6):768. PubMed ID: 24773561 [No Abstract] [Full Text] [Related]
20. Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications. Riveline JP; Danchin N; Ledru F; Varroud-Vial M; Charpentier G Diabetes Metab; 2003 Jun; 29(3):207-22. PubMed ID: 12909809 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]